On June 30, 2022, The Patented Medicine Prices Review Board (PMPRB) issued a Notice and Comment on its proposed approach for reviewing the prices of patented medicines during the period between the coming into force of the recently amended Patented Medicines Regulations on July 1, 2022 and the publication of its new Guidelines, which is slated for end of 2022 (“Interim Period”). The Notice and Comment period closed on July 18, 2022, and the submissions received during the comment period are available on the PMPRB’s website.
After carefully considering all the submissions, the Board has decided to proceed with the interim guidance as proposed in the Notice and Comment, with notable clarifications as discussed in its decision.
For updates on PMPRB activities, visit their website.